

Mehdi Hamadani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/178121/mehdi-hamadani-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

369
papers

7,158
citations

44
h-index

71
g-index

401
ext. papers

9,315
ext. citations

3.8
avg, IF

5.82
L-index

#	Paper	IF	Citations
369	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	0
368	New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.. <i>EJHaem</i> , 2022 , 3, 11-23	0.9	0
367	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221087511	5.7	0
366	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR Tcell, and BiTE recipients.. <i>Cancer Cell</i> , 2022 ,	24.3	1
365	HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2). <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, HSR22-171	7.3	
364	Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.. <i>Blood Reviews</i> , 2022 , 100913	11.1	0
363	Rap1A, Rap1B, and βAdrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. <i>Yale Journal of Biology and Medicine</i> , 2022 , 95, 45-56	2.4	
362	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
361	The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 2489-2489	2.2	0
360	Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. <i>Blood</i> , 2021 , 138, 1728-1728	2.2	
359	Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. <i>Blood</i> , 2021 , 138, 3575-3575	2.2	0
358	Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study. <i>Blood</i> , 2021 , 138, 3414-3414	2.2	2
357	Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1313-1320	3.5	
356	Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis. <i>Blood Advances</i> , 2021 ,	7.8	4
355	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
354	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021 , 35, 2672-2683	16.3	15
353	Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021 , 14, 65-70	2.7	11

352	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021 , 35, 2076-2085	10.7	10
351	Enteropathy-Associated T cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021 , 16, 140-147	4.4	1
350	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3006-3006	2.2	1
349	Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7521-7521	2.2	
348	Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7546-7546	2.2	1
347	Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS7574-TPS7574	2.2	2
346	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 790-800	21.7	56
345	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 363-370		2
344	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e775-e781	2	
343	Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. <i>Lancet Haematology,the</i> , 2021 , 8, e433-e445	14.6	10
342	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021 , 107, 301-310	3.8	1
341	Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. <i>British Journal of Haematology</i> , 2021 , 195, 429-432	4.5	1
340	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021 , 7, 993-1003	13.4	5
339	Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e619-e625	2	4
338	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021 , 56, 9-19	4.4	7
337	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 683-685	4.4	2
336	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 55.e1-55.e7		1
335	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 58-66		5

334	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021 , 137, 2634-2645	2.2	44
333	Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. <i>Blood</i> , 2021 , 137, 1416-1423	2.2	16
332	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20		12
331	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2763-2770	4.4	0
330	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 487-498	2.2	9
329	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 483.e1-483.e6		8
328	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e272-e276	2	0
327	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2763-2770	4.4	4
326	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 911.e1-911.e7		1
325	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 885-907		0
324	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 642-649		4
323	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2911-2921	4.4	2
322	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. <i>Blood</i> , 2021 , 138, 1278-1281	2.2	25
321	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021 , 96, 1374-1384	7.1	2
320	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. <i>Blood Advances</i> , 2021 , 5, 3528-3539	7.8	6
319	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. <i>Blood</i> , 2021 ,	2.2	9
318	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 720-728		4
317	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021 , 5, 5179-5189	7.8	0

316	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021 , 195, 757-763	4.5	2
315	A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. <i>Current Hematologic Malignancy Reports</i> , 2021 , 16, 19-24	4.4	2
314	Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 247-253	3.1	2
313	Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply. <i>JAMA Oncology</i> , 2020 , 6, 1984	13.4	
312	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. <i>British Journal of Haematology</i> , 2020 , 190, e98-e101	4.5	4
311	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e161-e166	4.7	22
310	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020 , 6, 1011-1018	13.4	19
309	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020 , 35, 307-315	3.2	2
308	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020 , 126, 2791-2801	6.4	2
307	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1247-1256	4.7	46
306	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e138-e141	4.7	7
305	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1288-1297	4.7	7
304	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1670-1678	4.7	6
303	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1518-1526	2.2	16
302	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 893-901	4.7	7
301	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020 , 190, 573-582	4.5	7
300	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1312-1317	4.7	27
299	Allogeneic Transplant Outcomes for T-Cell Lymphomas: A Single Center Analysis. <i>Blood</i> , 2020 , 136, 20-21	2.2	

298	Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. <i>Blood</i> , 2020 , 136, 22-22	2.2	1
297	Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 9-10	2.2	3
296	Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 35-36	2.2	2
295	A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2020 , 136, 9-10	2.2	1
294	Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT). <i>Blood</i> , 2020 , 136, 8-9	2.2	7
293	Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 35-37	2.2	9
292	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. <i>Blood</i> , 2020 , 136, 44-45	2.2	1
291	Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8000-8000	2.2	4
290	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1099-1105	4.7	3
289	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e177-e182	4.7	150
288	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 472-479	4.7	7
287	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e77-e85	4.7	21
286	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2020 , 61, 869-874	1.9	10
285	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1273-1283	2.2	131
284	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2229-2236	4.7	0
283	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020 , 26, 1569-1575	50.5	109
282	Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. <i>Journal of Experimental Pharmacology</i> , 2020 , 12, 549-557	3	4
281	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4

280	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2011-2017	4.7	6
279	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2011-2017	4.7	27
278	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1876-1885	4.7	1
277	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020 , 4, 3850-3852	7.8	24
276	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020 , 135, 97-107	2.2	29
275	Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 423-427	5.9	5
274	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020 , 4, 47-54	7.8	11
273	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. <i>Blood Advances</i> , 2020 , 4, 467-476	7.8	20
272	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020 , 126, 2279-2287	6.4	6
271	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019 , 125, 4417-4425	6.4	8
270	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2305-2321	4.7	68
269	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019 , 33, 1736-1746	10.7	29
268	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1859-1868	4.7	37
267	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2330-2337	4.7	6
266	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1604-1607	2.2	19
265	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1456-1464	4.7	13
264	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1689-1694	4.7	42
263	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1492-1497	4.7	17

262	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019 , 3, 1661-1669	7.8	13
261	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 210-215	2.7	1
260	A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e305-e309	4.7	1
259	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 56	7	7
258	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
257	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019 , 2, e196476	10.4	6
256	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019 , 34, 686-691	3.2	2
255	Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study. <i>Blood</i> , 2019 , 134, 2605-2605	2.2	2
254	BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML. <i>Blood</i> , 2019 , 134, 4602-4602	2.2	12
253	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019 , 134, 775-775	2.2	5
252	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 4465-4465	2.2	4
251	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 757-757	2.2	7
250	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 753-753	2.2	6
249	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3997-3997	2.2	1
248	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3483-3483	2.2	1
247	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019 , 134, 1525-1525	2.2	4
246	Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database. <i>Blood</i> , 2019 , 134, 1757-1757	2.2	1
245	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2510-2510	2.2	30

244	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)? <i>Blood</i> , 2019 , 134, 785-785	2.2	
243	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5891-5891	2.2	
242	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). <i>Blood</i> , 2019 , 134, 2005-2005	2.2	
241	A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. <i>Blood</i> , 2019 , 134, 1541-1541	2.2	
240	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019 , 134, 1554-1554	2.2	
239	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. <i>JAMA Oncology</i> , 2019 , 5, 715-722	13.4	30
238	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019 , 3, 2836-2844	7.8	24
237	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019 , 3, 875-883	7.8	13
236	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019 , 3, 360-369	7.8	59
235	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
234	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019 , 3, 2581-2585	7.8	10
233	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6986-6994	12.9	49
232	Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. <i>Oncologist</i> , 2019 , 24, 1488-1495	5.7	3
231	Allogeneic transplantation in elderly patients ≥5 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019 , 9, 97	7	6
230	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 95-102	2	3
229	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 827-833	4.7	14
228	Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1094-1106	4.4	20
227	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 6	22.4	15

226	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
225	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e33-e38	4.7	4
224	What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. <i>British Journal of Haematology</i> , 2019 , 184, 838-840	4.5	
223	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018 , 103, 717-727	6.6	31
222	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1210-1213	4.4	4
221	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018 , 124, 2306-2315	6.4	18
220	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018 , 5, e170-e180	14.6	28
219	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018 , 124, 2541-2551	6.4	44
218	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018 , 124, 1733-1742	6.4	40
217	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1379-1385	4.7	11
216	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 983-988	4.7	5
215	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 535-555	4.4	47
214	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. <i>British Journal of Haematology</i> , 2018 , 180, 534-544	4.5	48
213	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 343-350	13.4	89
212	Haploidentical Hematopoietic Cell Transplantation in Lymphomas 2018 , 245-260		
211	Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1664-1670 ²⁷	4.7	27
210	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1119-1124	4.7	15
209	Incidence and survival trends in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 181, 703-706 ⁵		31

208	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 478-485	4.7	27
207	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 78-85	4.7	7
206	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 ,	4.7	32
205	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2018 , 11, 105-111	2.7	6
204	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018 , 74, 130-136	2.7	24
203	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018 , 71, 95-99	2.7	14
202	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018 , 18, 593	4.8	15
201	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1610-1614	4.7	5
200	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018 , 124, 3455-3456	6.4	
199	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2862-2870	1.9	8
198	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 4193-4193	2.2	21
197	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018 , 132, 1015-1015	2.2	2
196	Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1658-1658	2.2	15
195	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 398-398	2.2	8
194	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study. <i>Blood</i> , 2018 , 132, 2874-2874	2.2	8
193	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 928-928	2.2	31
192	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7056-7056	2.2	1
191	A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7075-TPS7075	2.2	13

190	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018 , 132, 4153-4153	2.2	
189	Improvements in Clinical Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the United States from 2000-2014: Analysis of Surveillance Epidemiology and End Results Database. <i>Blood</i> , 2018 , 132, 2939-2939	2.2	
188	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. <i>Blood</i> , 2018 , 132, 3544-3544	2.2	
187	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 2918-2918 ^{2,2}	2.2	
186	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. <i>Blood</i> , 2018 , 132, 617-617	2.2	
185	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018 , 132, 1998-1998	2.2	
184	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2018 , 132, 969-969	2.2	
183	Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults 2018 , 83-109		2
182	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1163-1171	4.7	72
181	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 486-493	4.7	2
180	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. <i>Cancer</i> , 2018 , 124, 816-825	6.4	28
179	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018 , 182, 916-920	4.5	40
178	Advances in Transplantation for Lymphomas Resulting from CIBMTR Lymphoma Working Committee's Research Portfolio: A Five-Year Report (2013-2018). <i>Advances in Cell and Gene Therapy</i> , 2018 , 1, e17	1.2	
177	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018 , 2, 299-307	7.8	47
176	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018 , 2, 933-940	7.8	23
175	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 165-172	2	12
174	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. <i>Hematological Oncology</i> , 2017 , 35, 528-535	1.3	37
173	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 767-775	4.7	27

172	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1154-1161	2.2	354
171	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 853-856	4.7	21
170	Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2017 , 10, 47-56	2.7	5
169	Treatment of severe mucositis pain with oral ketamine mouthwash. <i>Supportive Care in Cancer</i> , 2017 , 25, 2215-2219	3.9	17
168	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 408-414	2	7
167	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017 , 130, 221-228	2.2	173
166	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1295-1302	4.7	7
165	Indolent lymphomas 2017 , 140-150		
164	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2017 , 10, 277-284	2.7	18
163	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 117	22.4	17
162	Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 201-206	2	7
161	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 305-311.e2	2	4
160	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017 , 179, 781-789	4.5	36
159	Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?. <i>Journal of Oncology Practice</i> , 2017 , 13, 798-806	3.1	10
158	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3002-3009	2.2	178
157	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017 , 8, 33-38	1.8	13
156	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19
155	Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017 , 92, E610-E611	7.1	5

154	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017 , 102, 1767-1775	6.6	36
153	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1955-1960	4.7	16
152	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1826-1838	4.7	89
151	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017 , 92, E563-E565	7.1	2
150	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 60-66	4.7	12
149	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 269-277	4.7	15
148	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
147	Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7508-7508	2.2	1
146	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7541-7541	2.2	
145	Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7062-7062	2.2	
144	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8012-8012	2.2	
143	Allogeneic stem cell transplant (AHCT) in the eighth decade: Age is just a number.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7045-7045	2.2	
142	Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2016 , 22, 666-78	1.7	6
141	Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016 , 175, 758	4.5	6
140	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1773-1780	4.7	4
139	Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. <i>Supportive Care in Cancer</i> , 2016 , 24, 4237-40	3.9	3
138	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3141-9	2.2	170
137	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , 2016 , 8, 435-47	3.8	15

136	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , 2016 , 128, 1786-1786	2.2	5
135	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. <i>Blood</i> , 2016 , 128, 3456-3456	2.2	1
134	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016 , 128, 683-683	2.2	3
133	Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8039-8039	2.2	2
132	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). <i>Blood</i> , 2016 , 128, 5192-5192	2.2	
131	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. <i>Blood</i> , 2016 , 128, 513-513	2.2	
130	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. <i>Blood</i> , 2016 , 128, 3551-3551	2.2	
129	Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. <i>Blood</i> , 2016 , 128, 4667-4667	2.2	
128	Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4630-4630	2.2	
127	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. <i>Blood</i> , 2016 , 128, 103-103	2.2	
126	Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. <i>Future Oncology</i> , 2016 , 12, 2631-2642	3.6	11
125	Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016 , 91, 322-9	7.1	54
124	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016 , 122, 3005-3014	6.4	32
123	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016 , 174, 235-48	4.5	88
122	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 802-14	4.7	23
121	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 379-86	2	15
120	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1056-1064	4.7	16
119	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1493-1503	4.7	45

118	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1543-1551	4.7	34
117	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016 , 127, 938-47	2.2	206
116	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 672-678	2	5
115	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 54-66	4.2	5
114	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2117-2125	4.7	70
113	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1155-66	4.7	87
112	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2091-2099	4.7	45
111	Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4424-8	5.9	53
110	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1746-53	4.7	39
109	Ibrutinib in Refractory Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1381-259.2		27
108	Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. <i>Cytotherapy</i> , 2015 , 17, 1785-92	4.8	24
107	Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1605-11	4.7	28
106	A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 428-432.e2	2	59
105	Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 199-207	2	1
104	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 552-8	4.7	9
103	Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies. <i>Blood</i> , 2015 , 126, 194-194	2.2	1
102	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015 , 126, LBA-8-LBA-8	2.2	54
101	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015 , 5, 81-8	2.3	1

100	A statistical model for predicting neutropenic fever.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18050-e18050		
99	Incidence of catheter-related venous thromboembolism in peripherally inserted central venous catheters vs tunneled chest central venous catheters in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20684-e20684	2.2	
98	Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7033-7033	2.2	
97	Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7009-7009	2.2	
96	Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015 , 126, 3168-3168	2.2	
95	Myeloablative or Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma? a Systematic Review and Meta-Analysis. <i>Blood</i> , 2015 , 126, 2097-2097	2.2	
94	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 4954-4954	2.2	
93	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 4360-4360	2.2	
92	Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2015 , 126, 198-198	2.2	
91	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. <i>Blood</i> , 2015 , 126, 4493-4493	2.2	
90	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 3169-3169	2.2	
89	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. <i>Blood</i> , 2015 , 126, 2711-2711	2.2	
88	Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1926-31	4.7	20
87	Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. <i>Journal of Clinical Oncology</i> , 2014 , 32, 273-81	2.2	110
86	Autologous hematopoietic cell transplantation: an update for clinicians. <i>Annals of Medicine</i> , 2014 , 46, 619-32	1.5	10
85	Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1729-36	4.7	79
84	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 89-97	4.7	99
83	Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 50-5	2	27

82	Allotransplantation for patients age \geq 60 years with non-Hodgkin lymphoma: encouraging progression-free survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 960-8	4.7	34
81	Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 951-9	4.7	30
80	Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanters?. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 292-4	4.7	2
79	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. <i>World Journal of Stem Cells</i> , 2014 , 6, 69-81	5.6	24
78	Reply to S. Fuji et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1860-1	2.2	
77	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , 2014 , 15, 1503-1512	21.7	207
76	Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 415-20	4.7	13
75	Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. <i>Seminars in Hematology</i> , 2014 , 51, 73-86	4	8
74	Cost and Efficacy of Upfront Plerixafor Versus a Just-in-Time (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization. <i>Blood</i> , 2014 , 124, 1127-1127	2.2	2
73	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014 , 124, 82-82	2.2	15
72	Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7048-7048	2.2	
71	A Statistical Model for Predicting Neutropenic Fever. <i>Blood</i> , 2014 , 124, 5258-5258	2.2	
70	Peripheral blood stem cell mobilization in multiple myeloma patients treated in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. <i>Journal of Clinical Apheresis</i> , 2013 , 28, 359-67	3.2	21
69	Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 746-53	4.7	65
68	Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4416-23	2.2	27
67	Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1006-12	4.7	62
66	Rituximab maintenance versus retreatment in follicular lymphoma. <i>Hematological Oncology</i> , 2013 , 31, 171-8	1.3	3
65	Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 173-9	4.7	32

64	Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1288-300	4.7	8
63	Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 625-31	4.7	68
62	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 2	22.4	35
61	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. <i>Bone Marrow Research</i> , 2013 , 2013, 414959		8
60	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2013 , 163, 315-25	4.5	30
59	Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013 , 122, 1718-1718	2.2	
58	Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1128-35	4.7	53
57	Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. <i>International Journal of Antimicrobial Agents</i> , 2012 , 40, 557-61	14.3	13
56	Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. <i>American Journal of Infection Control</i> , 2012 , 40, 931-4	3.8	59
55	Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1446-54	4.7	19
54	Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. <i>Journal of Oncology</i> , 2012 , 2012, 931071	4.5	9
53	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , 2012 , 119, 4786-97	2.2	108
52	Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. <i>Bone Marrow Research</i> , 2012 , 2012, 897215		1
51	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 332-332	2.2	12
50	Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis. <i>Blood</i> , 2012 , 120, 815-815	2.2	0
49	CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. <i>PLoS ONE</i> , 2011 , 6, e21968	3.7	11
48	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011 , 118, 1979-88	2.2	69
47	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. <i>Cancer Control</i> , 2011 , 18, 237-45	2.2	30

46	Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011 , 4, 149-56	2.7	8
45	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , 2011 , 29, 202-10	1.3	12
44	The evolving role of statins in hematopoietic stem and progenitor cell transplantation. <i>American Journal of Blood Research</i> , 2011 , 1, 57-64	1.6	2
43	Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 623-6	4.5	3
42	Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. <i>Journal of Clinical Oncology</i> , 2010 , 28, e629-32	2.2	30
41	Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 243-51	1.9	14
40	How we approach patient evaluation for hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1259-68	4.4	59
39	Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. <i>Hematological Oncology</i> , 2010 , 28, 3-12	1.3	5
38	Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 109	2.7	4
37	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 349-56	1.9	11
36	Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 547-53	4.7	37
35	Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1422-30	4.7	79
34	The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Clinical Leukemia</i> , 2009 , 3, 47-57		
33	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1232-1234	1.9	
32	Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. <i>Blood</i> , 2009 , 114, 2564-6	2.2	18
31	High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2008 , 81, 425-31	3.8	30
30	The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 351-2	4.7	7
29	Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 480-3	4.7	34

28	Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 556-67	4.7	30
27	Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 783-9	4.7	63
26	Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5134-6; author reply 5136-7	2.2	48
25	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1893-8 ^{1.9}		9
24	The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. <i>Blood</i> , 2008 , 111, 3901-2 ^{2.2}		40
23	CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). <i>British Journal of Haematology</i> , 2008 , 140, 122	4.5	2
22	Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 3300-3300	2.2	
21	A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .. <i>Blood</i> , 2008 , 112, 2008-2008	2.2	
20	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2008 , 112, 2170-2170	2.2	
19	Assessment of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients with Hematological Malignancies Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA). <i>Blood</i> , 2008 , 112, 4405-4405	2.2	
18	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas.. <i>Blood</i> , 2008 , 112, 3265-3265	2.2	
17	Review: isolated skeletal involvement in hairy cell leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 294-6	0.6	1
16	Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. <i>American Journal of Hematology</i> , 2007 , 82, 1120-1	7.1	2
15	Paraneoplastic Sweet's syndrome and the pathergy phenomenon. <i>Annals of Hematology</i> , 2007 , 86, 613-4 ³		12
14	Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?. <i>Journal of Oncology Pharmacy Practice</i> , 2007 , 13, 69-75	1.7	19
13	Gastrointestinal chronic graft-versus-host disease: management options. <i>Journal of Oncology Pharmacy Practice</i> , 2007 , 13, 49-51	1.7	2
12	Gastroparesis. <i>Southern Medical Journal</i> , 2007 , 100, 281-6	0.6	20
11	False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. <i>American Journal of the Medical Sciences</i> , 2007 , 334, 311-3	2.2	6

10	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 5129-5129	2.2	
9	Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2006 , 81, 959-62	7.1	17
8	Role of thiamine in managing ifosfamide-induced encephalopathy. <i>Journal of Oncology Pharmacy Practice</i> , 2006 , 12, 237-9	1.7	37
7	Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 795-6	5.1	2
6	Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 111-2	4.7	3
5	Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. <i>Southern Medical Journal</i> , 2006 , 99, 1142	0.6	2
4	Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. <i>Journal - Oklahoma State Medical Association</i> , 2006 , 99, 154-6	0.3	7
3	Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. <i>Journal of the College of Physicians and Surgeons--Pakistan: JCPSP</i> , 2006 , 16, 376-7	0.7	4
2	Granulocytic sarcoma manifesting as multiple skeletal lesions. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 139-43	2.2	8
1	Diffuse large B-cell lymphoma145-159		1